Combined Antibody Screening for Celiac and Diabetes Evaluation (CASCADE)

Pacific Northwest Research Institute

Status: Invitation-only

Conditions: Celiac Disease; Type 1 Diabetes

Treatments: Diagnostic Test: Combined Risk Score

Study type: Observational

Funder types: Other

Identifiers

NCT04677699

WSIRB# 2020-078

Details and patient eligibility

About

The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and celiac disease (CD) is feasible to prevent diabetic ketoacidosis (DKA), improve celiac disease diagnosis, and ultimately gain public health acceptance to facilitate future prevention. It has two arms, a Birth Cohort and a Kids (cross sectional) Cohort.

Enrollment: 64,410 estimated patients

Sex: All

Ages: 1 day to 7 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Child must be between 0 to 8 months in age or between 4 to 7 years in age. Child must be born in the state of Washington.

Exclusion criteria

Trial design

64,410 participants in 2 patient groups

Birth Cohort

Description:

Newborns less than 8 months old and born in the state of Washington.

Treatment:

Diagnostic Test: Combined Risk Score

Kids Cohort

Description:

Children ages 4-7 years and born in the state of Washington.

Treatment:

Diagnostic Test: Combined Risk Score